SCOPUS 정보 검색 플랫폼

Volumn 20, Issue 1, 2002, Pages 105-111

A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy - Southwest Oncology Group Study

(10) Whitehead, Robert P a Unger, Joseph M b Flaherty, Lawrence E c Kraut, Eric H d Mills, Glenn M e Klein, Catherine E f Chapman, Robert A g Doolittle, Gary C h Hammond, Neel i Sondak, Vernon K j

a UNIVERSITY OF TEXAS MEDICAL BRANCH (United States)

b Statistical Center (United States)

c WAYNE STATE UNIVERSITY (United States)

d OHIO STATE UNIVERSITY (United States)

e LOUISIANA STATE UNIVERSITY (United States)

f UNIVERSITY OF COLORADO (United States)

g HENRY FORD HOSPITAL (United States)

h UNIVERSITY OF KANSAS MEDICAL CENTER (United States)

i Billings Interhospital Oncol Proj (United States)

more..

Author keywords

Malignant melanoma; Pyrazine diazohydroxide

Indexed keywords

PYRAZINE DIAZOHYDROXIDE;

ADULT; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DNA SYNTHESIS INHIBITION; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; PYRAZINES;

EID: 0036210531 PISSN: 01676997 EISSN: None Source Type: Journal
DOI: 10.1023/A:1014484821460 Document Type: Article

Times cited : (6)

References (9)

1
- 0008686781
- edited by VT De Vita Jr, S Hellman, Rosenberg, SA. Lippincott Williams & Wilkins Publishers, Philadelphia
- (2001) Cutaneous Melanoma. Ch 42.2 in Cancer: Principles and Practice of Oncology, Sixth Edition
- Lotze, M.T.¹ Dallal, R.M.² Kirkwood, J.M.³ Flickinger, J.C.⁴

2
- 0008714236
- December
- (1993) Annual report to the food and drug administration, pyrazine diazohydroxide (NSC 361456)

3
- 0008721741
- Preclinical antitumor activity of pyrazine diazohydroxide, NSC 361456
- abstract
- (1986) Proceedings of AACR , vol.27 , pp. 275
- Plowman, J.¹ Haugwitz, R.D.² Narayanan, V.L.³ Baker, D.C.⁴ Hand, E.S.⁵ Rampal, J.B.⁶ Safavy, A.⁷

4
- 0025055188
- Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo
- (1990) Cancer Chemotherapy and Pharmacology , vol.25 , pp. 425-429
- Harrison Jr., S.D.¹ Plowman, J.² Dykes, D.J.³ Waud, W.R.⁴ Griswold Jr., D.P.⁵

5
- 0025633816
- In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts
- (1990) Cancer Treatment Reviews , vol.17 , pp. 109-117
- Fiebig, H.H.¹ Berger, D.P.² Winterhalter, B.R.³ Plowman, J.⁴

6
- 0023938928
- In vitro cytotoxicity of pyrazine-2-diazohydroxide: Specificity for hypoxic cells and effects of microsomal coincubation
- (1988) Invest New Drugs , vol.6 , pp. 3-9
- Brodfuehrer, J.I.¹ Moore, D.J.² Melder, D.C.³ Wilke, T.J.⁴ Powis, G.⁵

7
- 0023914099
- Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog
- (1988) Cancer Chemother Pharmacol , vol.21 , pp. 269-273
- Moore, D.J.¹ Brodfuehrer, J.I.² Wilke, T.J.³ Powis, G.⁴

8
- 0028057476
- Phase I and pharmacokinetic study of a new antineoplastic agent: Pyrazine diazohydroxide (NSC 361456)
- (1994) Cancer Res , vol.54 , pp. 114-119
- Vogelzang, N.J.¹ Mick, R.² Janish, L.³ Berezin, F.⁴ Schilsky, R.L.⁵ Ratain, M.J.⁶

9
- 15444354991
- Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer
- (1998) Clin Cancer Res , vol.4 , pp. 929-934
- Vogelzang, N.J.¹ Mani, S.² Schilsky, R.L.³ Ansari, R.H.⁴ Taber, D.⁵ Rhinehart, S.N.⁶ Garcia, J.C.⁷ Meyer, S.C.⁸ Mick, R.⁹ Brockstein, B.E.¹⁰ Stadler, W.M.¹¹ Ratain, M.J.¹² Vokes, E.E.¹³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.